Journal of acquired immune deficiency syndromes (1999) · 2026
Developing a drug-level feedback adherence counseling intervention for young MSM in the U.S.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Mahuvakar Shivani, Argueta-Rodriguez Juan, Montoya Rikki, Ghanooni Delaram, Ewart Leah Davis, Ross Emily, Moreira Carlos, Buccheri Renata, Sassaman Kevin, Martinson Tyler, Handley Margaret, Amico K Rivet, Heise M J, Kuncze Karen, Okochi Hideaki, Buchbinder Susan, Scott Hyman, Arnold Emily, Gandhi Monica, Spinelli Matthew
Аннотация
BACKGROUND: Young men who have sex with men (MSM) in the U.S. have suboptimal adherence to oral tenofovir-based pre-exposure prophylaxis (PrEP), undermining HIV prevention goals. Drug-level feedback using urine point-of-care tenofovir assays has improved adherence in Eastern and Southern African settings but has not been assessed among U.S. MSM.
SETTING: Community-based PrEP clinic in San Francisco and home-based remote counseling sessions among young MSM across the U.S.
METHODS: A two-phase study was conducted. Phase 1 involved qualitative interviews with 20 young MSM (mean age 25.7 years) from a San Francisco PrEP clinic, guided by the COM-B model and Behavior Change Wheel framework to identify barriers to adherence, informing the development of the PrEP2-BAY intervention. Phase 2 pilot-tested the PrEP2-BAY intervention remotely among 20 MSM (mean age 27.7 years), using at-home urine tenofovir tests and counselor-led feedback and action planning via Zoom. Acceptability was assessed qualitatively through the Theoretical Framework of Acceptability. Urine tenofovir levels were compared pre- and post-intervention.
RESULTS: Key barriers to PrEP adherence identified included mental health, substance use, relationship dynamics, and stigma. Participants preferred at-home testing with counselor guidance, leading to adaptation of PrEP2-BAY into an mHealth approach. In the pilot phase, participants reported high acceptability and perceived effectiveness. There was a trend toward improved urine tenofovir levels with all participants exhibiting positive urine test results post-intervention.
CONCLUSIONS: PrEP2-BAY demonstrated high acceptability with a trend toward improved adherence among young MSM. Further evaluation through a randomized controlled trial is recommended to assess efficacy and support broader implementation.
SETTING: Community-based PrEP clinic in San Francisco and home-based remote counseling sessions among young MSM across the U.S.
METHODS: A two-phase study was conducted. Phase 1 involved qualitative interviews with 20 young MSM (mean age 25.7 years) from a San Francisco PrEP clinic, guided by the COM-B model and Behavior Change Wheel framework to identify barriers to adherence, informing the development of the PrEP2-BAY intervention. Phase 2 pilot-tested the PrEP2-BAY intervention remotely among 20 MSM (mean age 27.7 years), using at-home urine tenofovir tests and counselor-led feedback and action planning via Zoom. Acceptability was assessed qualitatively through the Theoretical Framework of Acceptability. Urine tenofovir levels were compared pre- and post-intervention.
RESULTS: Key barriers to PrEP adherence identified included mental health, substance use, relationship dynamics, and stigma. Participants preferred at-home testing with counselor guidance, leading to adaptation of PrEP2-BAY into an mHealth approach. In the pilot phase, participants reported high acceptability and perceived effectiveness. There was a trend toward improved urine tenofovir levels with all participants exhibiting positive urine test results post-intervention.
CONCLUSIONS: PrEP2-BAY demonstrated high acceptability with a trend toward improved adherence among young MSM. Further evaluation through a randomized controlled trial is recommended to assess efficacy and support broader implementation.